---
schema_version: "secwatch.filing_event.v1"
accession: "0000920148-25-000054"
form_type: "8-K"
ticker: "LH"
cik: "0000920148"
company_name: "LABCORP HOLDINGS INC."
filed_at: "2025-04-29T23:59:59+00:00"
generated_at: "2026-05-23T04:34:50.013166+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Labcorp Q1 revenue $3.35B (+5.3% YoY), adj. EPS $3.84 vs $3.68; raises midpoint of FY adj. EPS guidance

## Summary
- Revenue $3.35B, GAAP diluted EPS $2.52 (down from $2.69), adjusted EPS $3.84 (up from $3.68).
- Raised adjusted EPS guidance midpoint to $15.70–$16.40; revenue and free cash flow guidance reaffirmed.
- Diagnostics segment revenue $2.63B (+6.0%), adjusted operating margin 16.3% (down 60bps due to Invitae and weather).
- Biopharma segment revenue $721.3M (+1.5%), adjusted operating margin 14.8% (up 80bps).
- Announced acquisitions of BioReference Health oncology assets and Inspira Health lab management; new liquid biopsy test Labcorp Plasma Complete.

## SEC filing metadata
- accession: 0000920148-25-000054
- form_type: 8-K
- ticker: LH
- cik: 0000920148
- company_name: LABCORP HOLDINGS INC.
- filed_at: 2025-04-29T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/920148/000092014825000054/0000920148-25-000054-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/920148/000092014825000054/lh-20250429.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000920148-25-000054
- JSON: https://secwatch.observer/filing/0000920148-25-000054.json
- Plain text: https://secwatch.observer/filing/0000920148-25-000054.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.